Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...
Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...
The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...
– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...
Zacks Investment Research on MSN
Can Merck's new drugs & pipeline ease Keytruda LOE concerns?
Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...
Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results